Schizophrenia News

Patients from community mental health centers who expressed concerns about developing drug-induced movement disorders tended to report worse health and daily functioning, according to study results presented at NEI Congress.

A digital medicine system appeared to improve clinical schizophrenia symptoms beyond the effects of oral pharmacotherapy alone, according to study results presented at Psych Congress.

The FDA can require a safety program called a Risk Evaluation and Mitigation Strategy, or REMS, for a medication with serious safety concerns to ensure the benefits outweigh the risks. An REMS is designed to reinforce behaviors and actions that support safe use of that medication to mitigate a specific risk.

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.

Patients with severe mental illness, particularly those with schizophrenia who are insured by Medicaid, have significant social risk factors that may adversely affect overall health, according to a study presented at Psych Congress.

Most frequent prescribers of long-acting injectable antipsychotics reported no changes in prescribing during the COVID-19 pandemic, according to results of a health care provider survey study presented at Psych Congress.

Healio Psychiatry’s five most-viewed stories in October highlight: the mental health effects of sibling bullying, the link between staying up late and suicidal thoughts, and regulatory developments.

Clinical high risk for psychosis syndrome appeared linked to impairment in reciprocal social behavior, according to results of a cross-sectional study published in Psychiatry Research.

Frequent nonmedical cannabis use and cannabis use disorder appeared linked to self-reported psychotic disorders, according to study results published in American Journal of Psychiatry.

Alkermes has announced that its schizophrenia/bipolar 1 disorder treatment Lybalvi is now available by prescription in the U.S.